Galectin Therapeutics Inc.
Company Snapshot: Galectin Therapeutics Inc.
Galectin Therapeutics (Nasdaq:GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer.
- Dec 11 2020 Galectin Therapeutics, Inc. to Present at the 4th Annual Digital NASH Summit on December 17, 2020
- Dec 4 2020 Galectin Therapeutics Inc. Recaps Results of Annual Meeting of Stockholders Presentation
- Dec 1 2020 Galectin Therapeutics to Webcast Corporate Update on December 3, 2020 after Annual Meeting of Stockholders
- Nov 9 2020 Galectin Therapeutics Provides Business Update And Reports Financial Results for the Quarter Ended September 30, 2020